Department of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima 890-0065, Japan.
Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Bioconjug Chem. 2024 Jun 19;35(6):804-815. doi: 10.1021/acs.bioconjchem.4c00145. Epub 2024 May 8.
Adjuvants are essential substances for vaccines and immunotherapies that enhance antigen-specific immune responses. Single-stranded oligodeoxynucleotides containing an unmethylated CpG motif (CpG ODNs) are agonistic ligands for toll-like receptor 9 that initiate an innate immune response. They represent promising adjuvants for antiviral and antitumor immunotherapies; however, CpG ODNs have some limitations, such as poor nuclease resistance and low cell membrane permeability. Therefore, an effective formulation is needed to improve the nuclease resistance and immunostimulatory effects of CpG ODNs. Previously, we demonstrated the selective delivery of a small molecule toll-like receptor 7 ligand to immune cells through sugar-binding receptors using sugar-immobilized gold nanoparticles (SGNPs), which significantly enhanced the potency of the ligand. In this study, we examined SGNPs as carriers for partially phosphorothioated A-type CpG ODN (D35) and an entirely phosphorothioated B-type CpG ODN (K3) and evaluated the functionality of the sugar moiety on SGNPs immobilized with CpG ODN. SGNPs immobilized with D35 (D35-SGNPs) exhibited improved nuclease resistance and the in vitro and in vivo potency was significantly higher compared with that of unconjugated D35. Furthermore, the sugar structure on the GNPs was a significant factor in enhancing the cell internalization ability, and enhanced intracellular delivery of D35 resulted in improving the potencies of the A-type CpG ODN, D35. SGNPs immobilized with K3 (K3-SGNPs) exhibited significantly higher induction activities for both humoral and cellular immunity compared with unconjugated K3 and D35-SGNPs. On the other hand, sugar structure on K3-SGNPs did not affect the immunostimulatory effects. These results indicate that the sugar moiety on K3-SGNPs primarily functions as a hydrophilic dispersant for GNPs and the formulation of K3 to SGNPs contributes to improving the immunostimulatory activity of K3. Because our CpG ODN-SGNPs have superior induction activities for antigen-specific T-cell mediated immune responses, they may be effective adjuvants for vaccines and immunotherapies.
佐剂是疫苗和免疫疗法的重要物质,可增强抗原特异性免疫反应。含有未甲基化 CpG 基序的单链寡脱氧核苷酸(CpG ODN)是 Toll 样受体 9 的激动配体,可引发先天免疫反应。它们是抗病毒和抗肿瘤免疫疗法有前途的佐剂;然而,CpG ODN 存在一些局限性,例如核酸酶抗性差和细胞膜通透性低。因此,需要有效的制剂来提高 CpG ODN 的核酸酶抗性和免疫刺激作用。以前,我们通过使用糖结合受体的糖固定化金纳米粒子(SGNPs)证明了小分子 Toll 样受体 7 配体向免疫细胞的选择性递送,这显著增强了配体的效力。在这项研究中,我们研究了 SGNPs 作为部分硫代磷酸化 A 型 CpG ODN(D35)和完全硫代磷酸化 B 型 CpG ODN(K3)的载体,并评估了固定在 SGNPs 上的 CpG ODN 上糖部分的功能。固定有 D35 的 SGNPs(D35-SGNPs)表现出改善的核酸酶抗性,并且其体外和体内效力明显高于未缀合的 D35。此外,金纳米粒子上的糖结构是增强细胞内化能力的重要因素,并且 D35 的细胞内递送的增强导致提高了 A 型 CpG ODN 的效力,D35。固定有 K3 的 SGNPs(K3-SGNPs)与未缀合的 K3 和 D35-SGNPs 相比,对体液和细胞免疫均表现出更高的诱导活性。另一方面,K3-SGNPs 上的糖结构不影响免疫刺激作用。这些结果表明,K3-SGNPs 上的糖部分主要作为金纳米粒子的亲水性分散剂起作用,并且 K3 制剂到 SGNPs 的贡献有助于提高 K3 的免疫刺激活性。由于我们的 CpG ODN-SGNPs 对抗原特异性 T 细胞介导的免疫反应具有更高的诱导活性,因此它们可能是疫苗和免疫疗法的有效佐剂。